neutral
Recently
Modern Diagnostic listing delivers muted debut despite healthy subscription
Modern Diagnostic’s IPO listing underwhelms relative to GMP, reflecting cautious sentiment toward SME stocks despite solid subscription demand.
Shares of Modern Diagnostic and Research Centre listed at around a 10 % premium on the BSE SME platform, falling short of grey market expectations. While the IPO was well subscribed, listing gains remained modest as investors booked profits early. Analysts point to cautious sentiment toward SME issues amid selective risk appetite. The company’s long term prospects now depend on execution consistency and expansion beyond regional healthcare markets.